Afin de soutenir la demande croissante, nous avons modifé la section Demandez au CCPP et l'avons rendu plus facile d'utilisation. Vous pouvez désormais sélectioner la catégorie qui vous interesse dans le menu déroulant et voir les questions qui ont déjà été posées et répondues. Vous pouvez également faire une recherche parmis les questions déjà soumises au CCPP depuis les débuts.
Questions et réponses les plus récentes
Is it acceptable to advertise a statement that says something along the lines of: "Drug X is the only drug containing active ingredient Y that is approved from clinical tests?" assuming that this statement is true? Would that change if the statement is more specific, such as "Drug X is the only epidural drug containing active ingredient Y that is approved from clinical tests?"
I cannot answer this question as I am not sure what you mean by “approved from clinical tests”. This is not the forum for assessment of particular claims anyways so I suggest submitting your particular question as an opinion (see the fee schedule on our website).
Is there guidelines on the use of reprint by sales rep ? Do we need to follow the innovative medecine code of ethics ? "Members’ promotional activities must never involve pro-active or solicited discussion of off-label indications, uses, dosages, or populations and must be consistent with the approved prescribing information in the product monograph." As it is a wide definition, as soon as we have the same indication, dosages, uses, population we are good ? Thanks
Distribution of materials through a sales representative is likely to be (or eventually become) a promotional activity. Off-label promotion would contravene section 9.1 of the Food and Drugs Act. Although rep activities do not fall under the scope of the PAAB, we can provide an opinion on whether the reprint is on-label and of sufficient quality to be used in the advertising context (note that both of these attributes -- not only avoiding off-label -- would be factors in determining adherence to section 9.1 of the Foods and Drugs Act).
In the context of a Consumer Brochure, is it permissible to provide DINs for a balanced list of medication options?
I’d advise against doing so as DINs tend to be used as the gating mechanism for patient information websites. i.e. promoting the DIN of your products in the consumer realm would likely invalidate the gating mechanism you are using.
Section 3.1.10 of the Code states that "Secondary endpoints should be identified as such and the primary endpoint of the study should be presented in close proximity when warranted." How do you know when presentation of the primary endpoint is warranted? Is it always necessary to present the primary endpoint when presenting data (i.e., a secondary endpoint) that is in the product monograph?
It is not always necessary (although it is often necessary). The primary endpoint is required to appear prior to the secondary endpoint when not doing so could mislead the audience in some way. There would be several circumstances in which that could be the case but I’ll present one scenario here to make the point. Let’s say, for example, that non-inferiority versus the active comparator was demonstrated on the primary endpoint in a pivotal trial which is included within the product monograph. It would be misleading to present product monograph superiority data for a secondary endpoint from that same pivotal study without first conveying the fact that the product was non-inferior in the primary outcome. Although, secondary endpoints which are not directionally consistent with the primary endpoint are generally not accepted, the presentation would be acceptable in this case as it is consistent with the product monograph.
The Guidance document 'Claims Based on Non-Inferiority Trials' states that "In the event the non-inferiority study failed to demonstrate superiority in the primary endpoint, one should not use secondary endpoints to suggest superiority." Does this still apply if the primary/secondary endpoints are unrelated (eg. primary endpoint is an efficacy measure, secondary endpoints are safety measures)?
Yes it still applies. Secondary endpoints should not be used from a failed study.
Hello. Can a pharmaceutical company post a tweet on its Twitter platform about its product winning a research/innovation prize? For example, "Congratulations to Product X for winning the 2017 YZ Prize!"
Assuming that this is a prescription product, PAAB would advise against this for a couple of reasons:
the status message that the product won a prize for innovation would not appear to fall within the permissible DTCRx elements of name, price and quantity (and would therefore appear to exceed section C.01.044 of the Food and Drug Regulations).
As with any openly visible company sponsored tweet that mentions product brand, the manufacturer would be required to ensure that user generated content does NOT allude to the therapeutic use (as this would link the identified product to it’s therapeutic use). This message may invite that type of post, and the work required to remove posts from third party platforms can sometimes be more laborious than removing posts from your own sites.
If we pay for a beauty expert to talk about one of our OTC products live on a tv show like Breakfast Television (on City TV), should the beauty expert mention live on the show that they are being paid by a pharmaceutical company?
OTC advertising which is broadcasted to the general public does not fall within the scope of the PAAB. Nonetheless, we direct you to the updated Canadian Code of Advertising Standards available at http://adstandards.com/en/Standards/canCodeOfAdStandards.pdf where you’ll find that interpretation guideline #5 (page 13) addresses your precise question.
Does a HCP-directed website for a Schedule D vaccine need to be gated?
The fact that the vaccine (Schedule D) website is intended for HCP’s does not, in and of itself, trigger the requirement for gating (BUT it does trigger the requirement for PAAB preclearance). The piece would require review under the PAAB code for HCP advertising with the consumer as a secondary audience. In addition to being clear that HCP’s are the intended audience, this also means that it would also be reviewed under the Health Canada Therapeutic Comparative Advertising: Directive and Guidance document and the Policy: Principles for Claims Relating to Comparison of Non-therapeutic Aspects of Non-prescription Drug Products. Some changes may be required to the HCP messaging to address the consumer regulations. One example would be that therapeutic claims in the consumer realm require the support of two separate RCTs. This will likely mean the removal of the therapeutic comparisons in the piece (even if they were previously approved in HCP advertising). The alternative, of course, would be to add a gate.
Hi! We would like to know what the role of PAAB is? Do you support innovation or the pharmaceuticals? This is not meant to be prejudiced in anyway. We've tried to work with pharmaceuticals to put a product that could eventually replace vaccines, replace the current international immunization plans, prevent outbreaks and epidemics.These are just starters. We've conducted full scale animal trials and safety trials and will soon be ready for Phase 1 trials for Universal Flu, HIV/AIDS, Cancer for leukemia and Hodgkin's, all enteric diseases and one to replace the immunization program. I see from PAAB's membership there are a lot of pharmaceutical and vaccine companies represented. We've approached several foundations, vaccine companies and pharmas and got similar "not interested" responses.
When we move ahead with this how do we not conflict with publishing certain types of diseases we're targeting with names of products and to announce we have found a way to replace current immunization programs without getting the ire of the scientific community?
How do we announce this on TV when the large pharmaceutical companies control them?
Incorporated in 1976, the Pharmaceutical Advertising Advisory Board (PAAB) is a not-for profit, self-financing organization funded entirely by the fees paid by advertisers for preclearance review (not for the acceptance). The highly trained PAAB staff runs the preclearance program to ensure that proposed advertising meets Code standards for the promotion of pharmaceutical products. The PAAB code can be found on the website at www.paab.ca
The code was created (and is maintained on an ongoing basis) by the PAAB Board of Directors. The following organizations are members of the PAAB and have appointed official representatives to its Board:
The Association of Faculties of Medicine of Canada
Association of Medical Advertising Agencies
Canadian Association of Medical Publishers
Canadian Generic Pharmaceutical Association
Canadian Medical Association
Canadian Pharmacists Association
Best Medicines Coalition
Consumer Health Products Canada
Innovative Medicines Canada
Consumer Council of Canada
Fédération des médecins omnipraticiens du Québec
The PAAB mission is to deliver pre-clearance review services that support trustworthy health product communications that comply with the Canadian regulatory framework. The PAAB's primary role is to ensure that healthcare product communication for prescription, non-prescription, biological and natural health products is accurate, balanced and evidence-based, and reflects current and best practice. The PAAB also monitors trends in health product advertising and promotion and adjusts its code and practices as required to fulfill its mandate.
The scope of the PAAB includes promotional healthcare product communication for prescription, non-prescription, biological and natural health products to health care professionals in all media. PAAB also provides advisory comments on direct-to-consumer materials for prescription drugs. PAAB's Scope evolves with the regulatory framework.
Please visit our website at www.paab.ca for more information and don't hesitate to call us at (905) 509-2275 if you have any questions. Also find us on LinkedIn, join the PAAB group and participate in the discussion!
Hi, We are a health clinic interested in running a publicly funded flu shot campaign for the public. We want have free coffee cards and lollipops to give to anyone who comes in and gets a flu shot. Are we allowed to advertise in a flyer and emails to the neighbourhood businesses specifying that anyone who comes in and gets a flu shot will get a lollipop ad free coffee cards? What are the regulations surrounding advertising our flu shot clinic? Thanks!
The activity described is not within the PAAB mandate or scope. This flyer is not directly promoting a product (i.e. a specific vaccine) but is advertising a clinic and the activities surrounding it. You may wish to consult with your local public health unit.